{"public_id":"co_26e5a9b0ad8952a0793b326072f5a9b8","status":"active","merged_into_public_id":null,"resolved_public_id":"co_26e5a9b0ad8952a0793b326072f5a9b8","name":"HPV18","description":"Human papillomavirus type 18, a high-risk oncogenic HPV type assessed separately in the study.","aliases":["human papillomavirus type 18","type 18"],"types":["virus type"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":3188919,"title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.","citation_count":1176,"url":"https://sah.borca.ai/papers/3188919"}],"claims":[{"public_id":"cl_2dd2d1e8ea324e19d3df2a442e648fd5","text":"Women positive for pooled oncogenic HPV testing but negative for HPV16 or HPV18 had a 10-year cumulative incidence of CIN3 or worse of 3.0%, while women negative on pooled HPV testing had an incidence of 0.8%.","corpus_id":3188919,"url":"https://sah.borca.ai/claims/cl_2dd2d1e8ea324e19d3df2a442e648fd5"},{"public_id":"cl_950705f2f06e9d97d6f4fd840b260973","text":"Women positive for HPV18 but negative for HPV16 had a 10-year cumulative incidence of CIN3 or worse of 13.6%.","corpus_id":3188919,"url":"https://sah.borca.ai/claims/cl_950705f2f06e9d97d6f4fd840b260973"},{"public_id":"cl_a25c6ec5cd0e503677a95e7f4127ff5c","text":"Distinguishing HPV16 and HPV18 from other oncogenic HPV types may identify women at greatest risk of CIN3 or worse and support less aggressive management of other women with oncogenic HPV infections.","corpus_id":3188919,"url":"https://sah.borca.ai/claims/cl_a25c6ec5cd0e503677a95e7f4127ff5c"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_26e5a9b0ad8952a0793b326072f5a9b8","url":"https://sah.borca.ai/concepts/co_26e5a9b0ad8952a0793b326072f5a9b8"}